← All trials
NCT04365127
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2020
- Primary completion
- Sep 1, 2020
- Completion date
- Apr 17, 2021
- First posted
- Apr 28, 2020
- Last posted
- Apr 28, 2020
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cedars-Sinai Medical CenterLead sponsor
- Cedars-Sinai Medical CenterSponsor investigator
- Cedars-Sinai Medical CenterOverall official - principal investigator
- IBSA Institut Biochimique SACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.